Artificial intelligence in urological oncology: a scoping review of clinical applications

Artificial intelligence (AI) is being applied across urological oncology, yet few recent reviews have integrated its use across the major genitourinary malignancies in diagnosis, prognostication, and treatment planning. This scoping review mapped the contemporary literature on AI applications in prostate cancer, bladder cancer, and renal cell carcinoma using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR)-informed approach. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from database inception to 15 May 2026, and 35 studies were included. Across the included studies, AI showed strong performance in selected settings, including an area under the receiver operating characteristic curve (AUC) of 0.91 for clinically significant prostate cancer detection on MRI in the prostate imaging: cancer AI (PI-CAI) study, pooled accuracy of 92.3% for renal cell carcinoma histopathologic classification in pathology-focused meta-analytic data, and high reported AUCs in selected bladder cancer recurrence and cytology-related models. In general, multimodal approaches often performed well and in several studies outperformed single-modality models. However, most studies were retrospective, reporting standards were inconsistent, and prospective validation remained limited. In the wider literature, prostate cancer has received the most attention, with fewer robust studies in bladder and kidney cancers. Overall, AI holds considerable promise for improving precision oncology in urology, but broader clinical implementation will require standardized datasets, external and prospective validation, interpretable model design, and appropriate regulatory and ethical oversight.

Authors

Institutions

Publication Details

Journal
Academia oncology.
Published
2026-11-16
DOI
https://doi.org/10.20935/acadonco8608
Primary Topic
AI in cancer detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Artificial intelligence in urological oncology: a scoping review of clinical applications

Smrati Sabnani, Harshit Rewari, Gurpremjit Singh, Supradeep Narayanaswamy
2 links
Academia oncology.
AI in cancer detection
article

Artificial intelligence in urological oncology: a scoping review of clinical applications

Smrati Sabnani, Harshit Rewari, Gurpremjit Singh, Supradeep Narayanaswamy
article en

Abstract

Artificial intelligence (AI) is being applied across urological oncology, yet few recent reviews have integrated its use across the major genitourinary malignancies in diagnosis, prognostication, and treatment planning. This scoping review mapped the contemporary literature on AI applications in prostate cancer, bladder cancer, and renal cell carcinoma using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR)-informed approach. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from database inception to 15 May 2026, and 35 studies were included. Across the included studies, AI showed strong performance in selected settings, including an area under the receiver operating characteristic curve (AUC) of 0.91 for clinically significant prostate cancer detection on MRI in the prostate imaging: cancer AI (PI-CAI) study, pooled accuracy of 92.3% for renal cell carcinoma histopathologic classification in pathology-focused meta-analytic data, and high reported AUCs in selected bladder cancer recurrence and cytology-related models. In general, multimodal approaches often performed well and in several studies outperformed single-modality models. However, most studies were retrospective, reporting standards were inconsistent, and prospective validation remained limited. In the wider literature, prostate cancer has received the most attention, with fewer robust studies in bladder and kidney cancers. Overall, AI holds considerable promise for improving precision oncology in urology, but broader clinical implementation will require standardized datasets, external and prospective validation, interpretable model design, and appropriate regulatory and ethical oversight.

Academia oncology.Vol. 3(4)
Medanta The Medicity (IN), University of Miami (US), Medanta The Medicity (IN)
Good health and well-being
AI in cancer detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon